Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.
Subject
MSB Article: ASX tumbles to three-month low; ASX CHESS outage

MSB Article: ASX plummets to six-week low in broad sell-off

MSB Article: ASX slips as tech declines; Mesoblast soars 47pc

MSB Article: Mesoblast surges on FDA ‘rare paediatric disease’ designation

MSB Article: ASX rebounds as Whitehaven, Mesoblast power up

MSB Article: ASX rebounds as Whitehaven, Mesoblast power up

MSB Article: Mesoblast taps Bell Potter for $98m equity raising

MSB Article: ASX closes higher but ends the week down 1pc

MSB Article: Mesoblast: the biotech that hasn’t – yet

MSB Article: ASX ends the session higher but posts first weekly loss in four

MSB Article: Mesoblast and Neuren offer new parables for biotech investment

MSB Ann: Change of Director's Interest Notice

MSB Ann: Mesoblast Director Appointed to Strategic Advisory Role

MSB Ann: MSB Reports Q3 Financial Results and Operational Highlights

MSB Ann: Third Quarter Results Presentation

MSB Ann: Third Quarter Financial Results on Form 6-K

MSB Ann: Mesoblast Third Quarter Financial Results Webcast

MSB Ann: Becoming a substantial holder

MSB Ann: Change in substantial holding

MSB Ann: Cleansing Notice

MSB Ann: Application for quotation of securities - MSB

MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

MSB Ann: Reinstatement to Official Quotation

MSB Ann: Proposed issue of securities - MSB

MSB Ann: Mesoblast Completes Private Placement

MSB Ann: Voluntary Suspension

MSB Article: Mesoblast rattles the tin for at least $37m, Bell Potter in tow

MSB Ann: Trading Halt

MSB Ann: Pause in Trading

MSB Article: ASX jumps 0.9pc in biggest daily jump in two months

MSB Article: ASX jumps 0.9pc in biggest daily jump in two months

MSB Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection

MSB Ann: Appendix 3G and Appendix 3H

MSB Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

MSB Ann: Pause in Trading

MSB Ann: Prospectus for Warrants Related to Oaktree Facility

MSB Ann: DREAM HF Trial Published in JACC

MSB Ann: MSB Q2 Financial Results and Operational Highlights

MSB Ann: Second Quarter Results Presentation

MSB Ann: Half Yearly Report and Accounts

MSB Ann: Mesoblast Second Quarter Financial Results Webcast

MSB Ann: Remestemcel Clinical and Potency Studies Presented at Tandem

MSB Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP

MSB Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD

MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Ys

MSB Ann: Biotech Showcase 2023 Presentation in San Francisco

MSB Article: Mesoblast receives $US30m debt extension

MSB Ann: Extension of Undrawn US$30 million Facility

MSB Ann: Proposed issue of securities - MSB

Register to track MSB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
OPT
PAR
PYC
RAC
TLX